Figure 1. Expression of single copy transgenic human mutant FUS reproduces age-dependent ALS phenotypes in C. elegans: (A) Validation of human FUS transgene expression by qPCR (taqman). B) Adult worms were scored daily on solid media for paralysis phenotype. Transgenic mFUS worms show increased progressive paralysis over 12 days compared to transgenic wtFUS worms (p< 0.0001). (C) Expression of mFUS does not affect lifespan compared to wtFUS expression. (D) Synaptic cholinergic transmission has been evaluated by exposing day 1 adult worms to the cholinesterase inhibitor aldicarb. Worms were scored over 4 hours for aldicarb induced paralysis. Day 1 adult mFUS worms were hypersensitive to aldicarb treatment compared to either wtFUS or N2 (p< 0.0001). (E) Motility was further assessed in liquid M9 media by using the PhylumTech WMicrotrackerOne instrument. Adult day 1 mFUS worms have decreased motility capacity in liquid media over 10 hours compared to wtFUS and N2 (p< 0.0001). (F) Representative photo of an adult day 9 old
unc-47p::mCherry;FUS worm with a degeneration event in the ventral neuronal processes of the GABAergic motor neurons (Highlighted in the magnified frame). (G) Quantification of neurodegeneration in transgenic worms at days 1, 5 and 9 of adulthood. At day 5 and 9 of adulthood mFUS worms show significantly higher neurodegeneration than wtFUS worms (p< 0.0001). (H) Representative photo of an adult day 9 old
unc-47p::mCherry;mtFUS worm with a dorsal degeneration event in the axon of the GABAergic motor neurons (Highlighted in the magnified frame). (I) Quantification of dorsal axonal degeneration events in adult day 9 worms. Dorsal axonal degeneration can be observed more frequently in mFUS worms compared to wtFUS or
unc-47p::mCherry control worms (p< 0.0001). (J) Representation of GABAergic neuronal health in the transgenic FUS populations. mFUS worms have a higher percentage of different degenerative events in the day 9 of adulthood (Ventral, dorsal or both ventro-dorsal degeneration).